ChEMBL logo

ChEMBL

spacer
ChEMBL Statistics
  Loading Statistics...
spacer

Compound Report Card

Compound Name and Classification

Compound ID CHEMBL614
CHEMBL614
Compound Name PYRAZINAMIDE
ChEMBL Synonyms PIRILENE | Pyrazine-2-Carboxamide | PYRAZINECARBOXAMIDE | TEBRAZID | PYRAFAT | PYRAZINAMIDE
Max Phase 4 (Approved)
Trade Names TEBRAZID | PIRILENE | PYRAFAT | PYRAZINAMIDE
Molecular Formula C5H5N3O

Additional synonyms for CHEMBL614 found using NCI Chemical Identifier Resolver

Compound Representations

Molfile Download MolFile
Canonical SMILES NC(=O)c1cnccn1
Standard InChI InChI=1S/C5H5N3O/c6-5(9)4-3-7-1-2-8-4/h1-3H,(H2,6,9)
Standard InChI Key IPEHBUMCGVEMRF-UHFFFAOYSA-N

Sources

  • British National Formulary
  • DrugMatrix
  • Drugs for Neglected Diseases Initiative (DNDi)
  • Orange Book
  • PubChem BioAssays
  • Scientific Literature
  • USP Dictionary of USAN and International Drug Names
  • WHO Anatomical Therapeutic Chemical Classification

Alternate Forms of Compound in ChEMBL


CHEMBL614

Molecule Features

CHEMBL614 compound icon
Drug Type:Synthetic Small Molecule Rule of Five:Y First In Class:N Chirality:Achiral Molecule Prodrug:Y Oral:Y Parenteral:N Topical:N Black Box:N Availability Type:Prescription-only

Mechanism of Action

Mechanism of Action ChEMBL Target References
70S ribosome inhibitor 70S ribosome PubMed
Fatty acid synthase inhibitor Fatty acid synthase PubMed

Indications

MESH Heading MESH ID EFO ID EFO Term Max phase for indication References
Tuberculosis, PulmonaryD014397EFO:1000049pulmonary tuberculosis4ClinicalTrials
DailyMed
Acquired Immunodeficiency SyndromeD000163EFO:0000765AIDS2ClinicalTrials
OsteomyelitisD010019EFO:0003102osteomyelitis0ClinicalTrials
TuberculosisD014376Orphanet:3389Tuberculosis4ClinicalTrials
DailyMed
DailyMed
DailyMed
Tuberculosis, Multidrug-ResistantD018088EFO:0007381multidrug-resistant tuberculosis2ClinicalTrials

Clinical Data

ClinicalTrials.gov PYRAZINAMIDE
The Cochrane Collaboration PYRAZINAMIDE

Compound Bioactivity Summary

Compound Assay Summary

Compound Target Summary

Calculated Compound Parent Properties

Mol. Weight Mol. Weight Monoisotopic ALogP #Rotatable Bonds Polar Surface Area Molecular Species
123.1 123.0433 -0.42 1 68.87 NEUTRAL


HBA HBD #Ro5 Violations HBA (Lipinski) HBD (Lipinski) #Ro5 Violations (Lipinski)
3 1 0 4 2 0


ACD Acidic pKa ACD Basic pKa ACD LogP ACD LogD pH7.4 Aromatic Rings Heavy Atoms QED Weighted
13.91 .87 -.71 -.71 1 9 0.55

Structural Alerts

There are no structural alerts for CHEMBL614

Compound Cross References

ATC J - ANTIINFECTIVES FOR SYSTEMIC USE
J04 - ANTIMYCOBACTERIALS
J04A - DRUGS FOR TREATMENT OF TUBERCULOSIS
J04AK - Other drugs for treatment of tuberculosis
J04AK01 - pyrazinamide

ChemSpider ChemSpider:IPEHBUMCGVEMRF-UHFFFAOYSA-N
DailyMed pyrazinamide
PubChem SID: 11111657 SID: 121269831 SID: 144209257 SID: 144213088 SID: 170464703 SID: 17389747 SID: 174007270 SID: 26752748 SID: 50105394 SID: 8139959 SID: 90341475
Wikipedia Pyrazinamide

UniChem Cross References

View the UniChem Connectivity matches for CHEMBL614



ACToR 98-96-4
BindingDB 228814
Brenda 101385 3666
ChEBI 45285
ChemicalBook CB7429387
DrugBank DB00339
DrugCentral 2328
eMolecules 531199 27678593
EPA CompTox Dashboard DTXSID9021215
FDA SRS 2KNI5N06TI
Guide to Pharmacology 7287
Human Metabolome Database HMDB0014483
IBM Patent System 691050E0FEE45FB8DD3AF71CD00C2BED
KEGG Ligand C01956
LINCS LSM-5425
Mcule MCULE-6846697749
MolPort MolPort-001-770-770 MolPort-023-219-632
NIH Clinical Collection SAM002554927
Nikkaji J3.990J
NMRShiftDB 20050094
PDBe PZA
PharmGKB PA451182
PubChem 1046
PubChem: Drugs of the Future 92309395
PubChem: Thomson Pharma 15119868
Rhea 45285
Selleck Pyrazinamide(Pyrazinoic-acid-amide)
SureChEMBL SCHEMBL24102
ZINC ZINC000000002005

UniChem REST Service Call:
https://www.ebi.ac.uk/unichem/rest/verbose_inchikey/IPEHBUMCGVEMRF-UHFFFAOYSA-N spacer
spacer